Gilead Sciences, Inc. vs Vanguard Value Index Fund ETF — how do they compare? Gilead Sciences, Inc. trades at $135.5 (market cap $168.35B), while Vanguard Value Index Fund ETF trades at $225.5. The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while Vanguard Value Index Fund ETF pays none, and Vanguard Value Index Fund ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.
| GILD | VTV | |
|---|---|---|
Market Cap | $168.35B | — |
Sector | Health | — |
52-Week High | $155.80 | $225.35 |
52-Week Low | $110.56 | $179.43 |
Enterprise Value | $191.42B | — |
Dividend Yield | 2.42% | — |
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →The fund employs an indexing investment approach designed to track the performance of the CRSP US Large Cap Value Index, a broadly diversified index predominantly made up of value stocks of large US companies. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VTV →